Table 1.

The most relevant reviewed manuscripts on children with CLD and COVID-19.

References	Country	Studydesign	Total number of patients	Age (years)*	Confirmed COVID**	Outcome **
						Hospitalization	ICUadmission	Survival
Singh et al. (5)	United States	R	n = 2,780 (M = 38%); n = 250/2,780 (9%) with CLD; all patients aged >10 years; percentage of children aged 10–18 years: not reported	55.2 (±14.6)	Not reported	Not reported	Not reported	Not reported
Di Giorgio et al. (6)	Italy	R	n = 369 children with CLD (M = 60%)	11.1 (±7.7)	2	0	0	All survived
Di Giorgio et al. (7)	Italy	R	148 patients; 47/148 (32%, M = 40%) children with CLD	12.3 (2.8–17.8)	0	NA	NA	NA
Heinz et al. (8)	United States	C	Case report: onset 4 days post-LDLT (Donor and recipients Sars-CoV-2 positive) → Mild respiratory symptoms → Graft hepatitis	6 month	1	1	1	Survived
Morand et al. (9)	France	C	Case report: 5 month post-LT → Mild respiratory symptoms: tachypnea → Mild Graft hepatitis	4	1	1	0	Survived
Dona et al. (10)	Europe	R	a) Survey by 18 pediatric transplant centers (solid organ and stem cell transplantation) b) Individual follow-up of 14 affected children (including stem cell transplantation and waiting list) and 5 solid organ transplant recipients	a) 0–17 years (no details reported)b) Not reported	a) No absolute numbers reported b) 14 cases, 5 solid organ transplant recipients	a) 10/18 centers reported <10 COVID-19 pediatric cases b) 14 cases, 5 solid organ transplant recipients	a) <5% of affected children b) Not reported, but 2 severe courses	a) All survived b) No details reported
Nicastro et al. (11)	Italy	R	Survey of 155 pLT recipients in the region of Lombardy	14.8 (0.3–17.9)	0 (2 suspected cases with close contact)	0	0	All survived
D'Antiga et al. (12)	Italy	R	Cases series of 3 Sars-CoV-2 positive patients out of a cohort of n = 700 pediatric LT recipients	Not reported	3	0	0	All survived

^*Mean or median;

^**data on children alone; C, case report; R, retrospective; P, prospective; M, male; NA, not applicable.